收藏切换
Cost-effectiveness analysis of denosumab in the treatment of postmenopausal women with osteoporosis
收藏切换
Jiahui ZHANG1, 2, Chenlin DAI3, Xiaoning HE1, 2, *
World Clinical Drug | 2022, 43(12) : 1610 - 1619
Less
收藏切换
World Clinical Drug | 2022, 43(12): 1610-1619
• Article •
Cost-effectiveness analysis of denosumab in the treatment of postmenopausal women with osteoporosis
Full
Jiahui ZHANG1, 2, Chenlin DAI3, Xiaoning HE1, 2, *
Affiliations
  • 1.School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China
  • 2.Center for Social Science Survey and Data, Tianjin University, Tianjin 300072, China
  • 3.Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin 300052, China
Published: 2022-12-10 doi: 10.13683/j.wph.2022.12.016
Outline
收藏切换
Objective

To evaluate the economic value of denosumab compared with alendronate and zoledronate in the treatment of postmenopausal women with osteoporosis (OP) from the perspective of Chinese health system.

Methods

Markov model was established and the treatment period was set to 5 years. The clinical efficacy, health benefits and cost data were obtained from published literatures. Lifetime disease outcomes, effectiveness and costs were calculated under each intervention. With the incremental cost-effectiveness ratio (ICER) as the index, the economy of each intervention was evaluated under the threshold of 3 times GDP per capita. Situation analysis, single factor sensitivity analysis and probability sensitivity analysis were used to test the robustness of the results.

Results

The total costs were 19 268, 18 324 and 22 386 yuan in the groups of denosumab, alendronate and zoledronate, respectively. Total quality-adjusted life year (QALY) were 7.58, 7.53 and 7.56. Compared with alendronate, denosumab increased QALY by 0.05, ICER was 18 279 yuan per QALY, which was much lower than 1 times GDP per capita and more economical. Compared with zoledronate, denosumab resulted in an additional 0.03 QALYs and a lower cost, showing absolute advantage. Sensitivity analysis proved the robustness of the results.

Conclusion

In the treatment of postmenopausal women with OP, denosumab is more economical than alendronate and has absolute advantages over zoledronate.

postmenopausal women with osteoporosis  /  cost-effectiveness analysis  /  denosumab  /  alendronate  /  zoledronate
张嘉会, 戴晨琳, 贺小宁. 地舒单抗治疗绝经后女性骨质疏松症的成本-效果分析. 世界临床药物, 2022 , 43 (12) : 1610 -1619 . DOI: 10.13683/j.wph.2022.12.016
Jiahui ZHANG, Chenlin DAI, Xiaoning HE. Cost-effectiveness analysis of denosumab in the treatment of postmenopausal women with osteoporosis[J]. World Clinical Drug, 2022 , 43 (12) : 1610 -1619 . DOI: 10.13683/j.wph.2022.12.016
Year 2022 volume 43 Issue 12
14
4
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2022.12.016
  • Receive Date:2022-09-06
  • Online Date:2026-11-18
  • Published:2022-12-10
Article Data
Affiliations
History
  • Received:2022-09-06
Affiliations
    1.School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China
    2.Center for Social Science Survey and Data, Tianjin University, Tianjin 300072, China
    3.Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin 300052, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.12.016
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT